{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:31:26Z","timestamp":1783002686649,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["30 CA91842"],"award-info":[{"award-number":["30 CA91842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clml.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T06:01:52Z","timestamp":1673935312000},"page":"266-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Dynamics of Financial Toxicity in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark A.","family":"Fiala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-4213","authenticated-orcid":false,"given":"Alice E.","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-8990","authenticated-orcid":false,"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-1715","authenticated-orcid":false,"given":"Keith E.","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.01.008_bib0001","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","article-title":"Limits on Medicare's ability to control rising spending on cancer drugs","volume":"360","author":"Bach","year":"2009","journal-title":"The New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.008_bib0002","unstructured":"Keisler-Starkey K., Bunch L N 2021. Health Insurance Coverage in the United States: 2020. Available at: https:\/\/www.census.gov\/library\/publications\/2021\/demo\/p60-274.html. Retrieved January 11, 2013"},{"key":"10.1016\/j.clml.2023.01.008_bib0003","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of Myeloma Therapy","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ book"},{"key":"10.1016\/j.clml.2023.01.008_bib0004","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1002\/cncr.29510","article-title":"Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families","volume":"121","author":"Zajacova","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after Cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann oncol: official j Eur Soc Med Oncol"},{"key":"10.1016\/j.clml.2023.01.008_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","article-title":"A systematic review of financial toxicity among Cancer survivors: we can't pay the co-pay","volume":"10","author":"Gordon","year":"2017","journal-title":"The patient"},{"issue":"1","key":"10.1016\/j.clml.2023.01.008_bib0007","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.clml.2023.01.008_bib0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nursing"},{"key":"10.1016\/j.clml.2023.01.008_bib0009","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: The COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.01.008_bib0010","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1200\/jco.2015.33.15_suppl.6618","article-title":"Grading financial toxicity based upon its impact on health-related quality of life (HRQol)","volume":"33","author":"de Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.008_bib0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/ijgc-2021-002475","article-title":"Evaluating meaningful levels of financial toxicity in Gynecologic Cancers","volume":"31","author":"Esselen","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clml.2023.01.008_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-020-07178-5","article-title":"Education level as a predictor of survival in patients with multiple Myeloma","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2023.01.008_bib0013","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10900-017-0327-6","article-title":"Neighborhood socioeconomic status and health: a longitudinal analysis","volume":"42","author":"Robinette","year":"2017","journal-title":"Commun Health"},{"key":"10.1016\/j.clml.2023.01.008_bib0014","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple Myeloma","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.01.008_bib0015","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.clml.2020.11.021","article-title":"Prevalence and survival impact of self-reported symptom and psychological distress among patients with multiple Myeloma","volume":"21","author":"Richter","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2023.01.008_bib0016","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple Myeloma: a cross-sectional Pilot Study","volume":"2","author":"Huntington","year":"2015","journal-title":"The Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.01.008_bib0017","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2021-153271","article-title":"Financial toxicity and associated patient-reported quality of life in Plasma Cell Disorders","volume":"138","author":"Schmidt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.008_bib0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.01.008_bib0019","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1007\/s00520-020-05719-z","article-title":"Financial toxicity and employment status in cancer survivors. A systematic literature review","volume":"28","author":"Mols","year":"2020","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.clml.2023.01.008_bib0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jha2.231","article-title":"Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma","volume":"2","author":"Biran","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2023.01.008_bib0021","doi-asserted-by":"crossref","first-page":"e1094","DOI":"10.1200\/OP.20.00721","article-title":"Longitudinal trends of financial toxicity in patients with Lung Cancer: a prospective Cohort Study","volume":"17","author":"Friedes","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2023.01.008_bib0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","article-title":"Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare","volume":"2","author":"Gormley","year":"2021","journal-title":"Blood Cancer Discov"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:08Z","timestamp":1761871268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2152265023000198"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Dynamics of Financial Toxicity in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}